Premium
High‐dose cutaneous exposure to mite allergen induces IgG‐mediated protection against anaphylaxis
Author(s) -
Hirai T.,
Yoshioka Y.,
Takahashi H.,
Handa T.,
Izumi N.,
Mori T.,
Uemura E.,
Nishijima N.,
Sagami K.,
Yamaguchi M.,
Eto S.,
Nagano K.,
Kamada H.,
Tsunoda S.,
Ishii K. J.,
Higashisaka K.,
Tsutsumi Y.
Publication year - 2016
Publication title -
clinical and experimental allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 154
eISSN - 1365-2222
pISSN - 0954-7894
DOI - 10.1111/cea.12722
Subject(s) - allergen , immunology , immunoglobulin e , medicine , mite , allergy , atopic dermatitis , sensitization , anaphylaxis , house dust mite , antibody , biology , botany
Summary Background The relationship among natural allergen exposure, induction of blocking antibody and the occurrence of atopic allergy—particularly in the presence of IgE production—is debatable. Objective To clarify the relationship between the dose of cutaneous exposure to dust mite allergen and susceptibility to the IgE‐mediated allergic response in relation to IgG production. Methods NC /Nga mice were epicutaneously exposed to various doses of Dermatophagoides pteronyssinus allergen to induce atopic dermatitis–like skin lesions. We then evaluated the skin lesions, induction of mite‐specific immune responses, and susceptibility to anaphylaxis. Results Dose‐dependent exacerbation of atopic dermatitis–like skin lesions and increases in mite‐specific IgG and IgE production were observed. However, mice exposed to relatively low doses of mite allergen showed hypersusceptibility to mite allergen–specific anaphylaxis. We also showed that adoptive transfer of total IgG from Dp‐sensitized mice rescued mice from the hypersusceptibility seen in those exposed to low doses of mite allergen. Conclusions and Clinical Relevance High‐dose cutaneous exposure to dust mites induced effective blocking IgG production, even if accompanied by IgE production. Our data might support the concept that an increase in IgG titre, not a decrease in IgE titre, is a marker of clinical improvement in allergen‐specific immunotherapy.